InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Henderson Molly, Chief Financial Officer. Director active across 2 companies, notably UroGen Pharma Ltd.. Cumulatively, 9 reports have been published. Total volume traded: €65k. The latest transaction was filed on 19 May 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations9 total
012,000 shares0
Common Stock
SEC:0001209191-22-031085:0·
6,000 shares
Common Stock
SEC:0001209191-22-029446:0·
Ideal exit: 7 Feb 2023 (T+270)
020,000 shares0
Common Stock
SEC:0001209191-22-023561:0·
666 shares
Ordinary Shares
SEC:0001209191-22-006385·
666 shares
Ordinary Shares
SEC:0001209191-22-006385:0·
5,000 shares
Ordinary Shares
SEC:0001209191-21-067439·
5,000 shares
Ordinary Shares
SEC:0001209191-21-067439:0·
€32,5952,500 shares@ €13.03790.0023% mcap100.0% of flow
Common Stock
SEC:0001209191-21-033402·
Ideal exit: 11 Feb 2022 (T+270)
€32,5952,500 shares@ €13.03790.0023% mcap50.0% of flow
Common Stock
SEC:0001209191-21-033402:0·
Ideal exit: 11 Feb 2022 (T+270)
9 of 9 declarations
About Henderson Molly
Molly Henderson is the Chief Financial Officer of UroGen Pharma Ltd. and Phathom Pharmaceuticals, Inc. In these roles, she is responsible for financial management and strategy, contributing to the financial sustainability and growth of these biopharmaceutical companies.
